What is Wall Street's Target Price for Burning Rock Biotech Ltd (BNR) Stock Monday? – InvestorsObserver

Science & Technology

Wall Street is positive on Burning Rock Biotech Ltd (BNR). On average, analysts give the stock a Strong Buy rating. The average price target is $29.55, which means analysts expect the stock to increase by 172.85% over the next twelve months. That average ranking earns the stock an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating BNR a Strong Buy today. Find out what this means to you and get the rest of the rankings on BNR!

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What’s Happening With Burning Rock Biotech Ltd Stock Today?

Burning Rock Biotech Ltd (BNR) stock is trading at $10.83 as of 10:56 AM on Monday, Dec 27, a rise of $0.32, or 3.1% from the previous closing price of $10.50. The stock has traded between $10.31 and $10.83 so far today. Volume today is low. So far 365,894 shares have traded compared to average volume of 581,634 shares. Click Here to get the full Stock Report for Burning Rock Biotech Ltd stock.
Stock Price data may be delayed up to 15 minutes.
Copyright © 2021. Portions of this content may be copyrighted by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. All Rights Reserved. Portions of this content protected by US Patent numbers 7,865,496, 7,856,390, and 7,716,116. Investing in stocks, bonds, option and other financial instruments involve risks and may not be suitable for everyone. Portfolio results are unaudited and based on varying investment expiration dates. Terms of Service | Privacy Policy

source